2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - Great Hall BC
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

904 Update on the phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Wei Ying Jen, BM BCh, FRCPath, Courtney DiNardo, MD, MSCE2, Nicholas Short, MD3, Aziz Farhat, MD, BS4, Georgina El Hajjar, MD5, Baili Zhang, N/A6, Dzifa Duose, PhD7, Naval Daver, MD8, Yesid Alvarado Valero, MD9, Jo Ishizawa, MD, PhD10, Tapan Kadia I, MD11, Branko Cuglievan, MD12, Kelly Sharon Chien, MD13, Nitin Jain, MD14, Hussein Ali Abbas, MD, PhD15, Abhishek Maiti, MBBS16, Jayastu Senapati, MBBS, MD, DM17, Elias Jabbour, MD18, Guillermo Montalban-Bravo, MD19, Miriam B. Garcia, DO20, Maro Ohanian, DO21, Lucia Masarova, MD22, Sanam Loghavi, MD23, Farhad Ravandi, MD24, Michael Andreeff, MD, PhD25, Hagop Kantarjian, MD26, Guillermo Garcia-Manero, MD27, Ghayas C. Issa, MD28
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

The menin–KMT2A interaction is a dependency in acute leukemia caused by NPM1 mutations (NPM1m) or rearrangements of KMT2A (KMT2Ar) or nucleoporin 98 (NUP98r). The combination of the menin inhibitor revumenib and venetoclax is synergistic in preclinical models of these subtypes. NPM1m, KMT2Ar and NUP98r are observed in 30%, 5% and 1% of newly diagnosed (ND) AML, respectively. We designed a phase 2 study to evaluate the all-oral combination of decitabine/cedazuridine, venetoclax and revumenib (SAVE, NCT05360160) in these AML subtypes.

Methods

Pts aged ≥12 years with ND NPM1m, KMT2Ar or NUP98r AML or mixed-lineage acute leukemia (MPAL) who were not candidates for intensive chemotherapy were eligible. Decitabine/cedazuridine was administered at 35mg/100mg QD D1-5, venetoclax at 400mg (target dose with ramp up) QD D1-14, and revumenib at 270mg (without strong CYP3A inhibitors) or 160mg (with strong CYP3A inhibitors) Q12h D1-28. All pts underwent bone marrow (BM) assessment on C1D14, in addition to end of cycle assessment, with revumenib held after D21 if BM blasts were <5%. Revumenib maintenance following hematopoietic stem cell transplant (SCT) was resumed for 1 year.

Measurable residual disease (MRD) was assessed by flow cytometry (FC, sensitivity 10-4) in all pts. Pts with NPM1m also had NGS MRD assessment (sensitivity 5×10-5, Invivoscribe, USA). MEN1 mutation testing using ddPCR was performed at relapse.

Results

At data cut on 7/14/26, 30 pts, 28 evaluable for response, have been treated (2 pts are still receiving cycle 1). Pts received a median of 3 (range, 1-20) treatment cycles. 17 (57%) had NPM1m and 13 (43%) had KMT2Ar (1 with KMT2A::NUP98). The median age was 69 years (range, 17-83); 40% had secondary or therapy-related AML. By ELN2022 criteria, 50% had favorable, 10% intermediate and 40% adverse risk disease. Cytogenetics were complex in 13%. Signaling co-mutations occurred in 59% and 38% of the NPM1m and KMT2Ar, respectively. MDS mutations occurred in 41% of NPM1m; 2 pts had FLT3-ITD allele ratios <0.05; one KMT2Ar pt had a TP53 mutation.

The overall response rate (CRc + PR + MLFS) was 89% (25/28 pts, 95% CI, 73-96). The CRc rate was 79% (95% CI, 61-90), with MRD negative CRc rate by FC of 91% (95% CI, 73-98). All KMT2Ar responders had complete cytogenetic remission by FISH. NGS MRD results at the end of cycle 2 or later were available for 13 NPM1m pts with CR/CRh. The NPM1m MRD negative rate by NGS was 69% (9/13, 95% CI, 42-87). Of the 4 remaining pts, 1 had detectable MRD but below the 5×10-5 assay sensitivity. The patient underwent SCT with subsequent MRD clearance. The remaining 3 never cleared NPM1 MRD, did not proceed to SCT, and subsequently relapsed.

At a median follow-up of 13 months (95% CI, 11-24), the median OS was 19 months (95% CI, 10-NE), with a 1-year OS of 67% (95% CI, 50-89). The median EFS was not reached and the 1-year EFS was 58% (95% CI, 41-82). In patients achieving a CR/CRh, the median duration of response (DOR) was not reached; 72% (95% CI, 49-100) of NPM1m and 86% (95% CI, 63-100) of KMT2Ar pts were still in remission at 1 year. SCT was performed in 9 (32%) pts; 4 (25%) NPM1m and 5 (42%) KMT2Ar. Of the 5 pts (3 NPM1m and 2 KMT2Ar) who have relapsed, 3 have undergone MEN1 mutation testing, with an M327I mutation detected in 2 at relapse.

The 30-day mortality rate was 11%; 2 patients died during induction after D14 BM showing MLFS, 1 with AML post-primary myelofibrosis withdrew consent on D3 of treatment to proceed to hospice. The median cycle length was 38 days (range, 32-112) for C1 and 42 days (range, 31-75) for C2. The most common grade ≥3 adverse events were thrombocytopenia (50%), febrile neutropenia (46%) and neutropenia (36%). QTc prolongation occurred in 10 (36%); all episodes were grade 1-2 and did not require dose modification. Differentiation syndrome (DS) occurred in 7 (25%) pts; 2 pts had grade 3 DS which promptly resolved with steroids. Nausea occurred in 64%; all events were grade 1-2, not requiring dose modifications. Five pts resumed revumenib as maintenance post-SCT, of whom 2 had detectable NPM1m by NGS MRD post-SCT. These two patients subsequently cleared NPM1 MRD after resuming revumenib maintenance and are continuing on therapy.  

Conclusion

SAVE, an all-oral combination, shows promising activity in adults with ND NPM1m or KMT2Ar AML who are ineligible for intensive chemotherapy. Longer follow-up is required to establish the durability of response and survival.
Wei Ying Jen, BM BCh, FRCPath: No relevant conflicts of interest to declare.